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Abstract
BACKGROUND: The aim of the study was to assess myocar-
dial perfusion in women with systemic lupus erythomatosus
(SLE) and no symptoms of coronary artery disease (CAD).
MATERIAL AND METHODS: Twenty two women with SLE of
mean age 40.5 ± 7.2 were enrolled in the study. The average
duration time of the disease was from 2 to 19 years, mean 8 ±
± 4.6 years. The inclusion criterion was the absence of steno-
cardial symptoms. The myocardial perfusion was studied by
using Single Photon Emission Computerized Tomography
(SPECT) utilising 99mTc-MIBI ands a triple-head gamma-cam-
era. We also analyzed risk factors of heart ischemic disease in
our group.
RESULTS: Myocardial perfusion stress scanning showed ab-
normal perfusion in 12 patients, 54.5% of the whole group, most-
ly in the anterior wall. At rest hypoperfusion abnormalities were
found in 7 individuals. In patients with positive myocardial per-
fusion, out scanning, risk factors of CAD were more pronounced
than in a sub-group with a negative result of myocardial perfu-
sion scanning.
CONCLUSIONS: In young women with SLE  and no symptoms
of coronary artery disease, myocardial pefusion defects may
be detected by means of myocardial perfusion scintigraphy.
Exercise and resting electrocardiography tests could be not su-
fficient for CAD diagnosis in women with SLE. The presence of
coronary artery disease risk factors in women with SLE could
be an indication to perform myocardial perfusion SPECT sca-
nning.
Introduction
The prevalence of systemic lupus erythematosus (SLE) is con-
sidered to be 1 in 500 to 1000 women. Clinical symptoms may
involve many organs. Along with the introduction of new treat-
ment methods, the clinical image and causes of mortality have
changed. Until now renal failure and infections were the most com-
mon causes of death in SLE. A rapid decrease in mortality in SLE
was caused by intensive immunosupressive therapy and a wide
use of antibiotics [1]. At the same time an increase of cardiovas-
cular complications was observed [2]. Ischaemic heart disease
has been described in young women with SLE from the early 70s.
In 1976 Urowitz stated that cardiac deaths occur in the early acute
phase of the disease or after many years duration [3]. Cardiovas-
cular mortality is considered to be 9–45% of all deaths in patients
with SLE [2]. This affects mostly young women. It is suspected
that the rate of CAD is much higher, as most of patients have no
symptoms of disease. This theory was confirmed by post mortem
studies [4]. The aim of this study was to assess the prevalence of
asymptomatic cardiac ischemic disease and risk factors of CAD
in women with SLE utilizing myocardial perfusion 99mTc-MIBI
SPECT.
Material and methods
Twenty two women with SLE of mean age 40.5 ± 7.2 mean
were enrolled in the study. Systemic lupus erythomatosus  was
diagnosed based on the criteria of American Rheumatic Associa-
tion (ARA). The average duration time of the disease was from
2 to 19 years, mean 8 ± 4.6 years. The inclusion criterion was the
absence of stenocardial symptoms. The severity of SLE was cal-
culated based on SLEDAI scale. All enrolled women had low SLE
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activity with a mean SLEDAI score 4.2 ± 3.1. Of other clinical symp-
toms, skin changes were seen in 13 patients, arthritis in 7, throm-
bocytopenia in 5, myositis, phlebitis and haemolytic anaemia in 2.
All women were on steroid therapy in support doses varying
from 10 to 20 mg/48 h; some of them were also on chlorochinine or
azathioprine treatment. All patients had resting electrocardiography
(ECG), echocardiography and exercise electrocardiography prior
to our study. Romhilt-Estes and Sokolow-Lyon indexes were used
to assess heart muscle hypertrophy. Myocardial perfusion sca-
nning was performed in the Department of Nuclear Medicine of the
Medical University of Gdańsk in two days protocol after i.v. ad-
ministration 99mTc-MIBI (FAM, Łódź, Poland), of activity 20 mCi
(740 MBq). An exercise test was performed 30 minutes after the
administration of the radiotracer, using the modified treadmill Bruce
protocol. The rest test was performed 60 minutes after the adminis-
tration of the radiotracer. SPECT scanning was performed using
a three-head gammacamera Multispect-3 (Siemens, Erlangen, Ger-
many). The data were collected into a 64 × 64 matrix.
Plasma levels of cholesterol and its fractions, plasma glucose,
homocysteine, antiphospholipid antibodies and/or lupus antico-
agulant (LAC) were assessed. We also checked the blood pres-
sure values in each patient. Each woman was asked about tobac-
co smoking habits and menopausal age.
The study protocol has been approved by the local Ethics Com-
mittee. Written informed consent was obtained from all subjects.
Results
No ischemic or heart muscle hypertrophy changes were found
in the rest electrocardiography examination. The ECG exercise
test was positive only in one case. In echocardiographic study the
segmental hypokinetics of the heart muscle was observed in
5 patients.
Myocardial SPECT
SPECT stress scanning showed abnormal myocardial in
12 patients, 54.5% of the whole group. At rest hypoperfusion ab-
normalities were found in 7 patients. Localization of heart perfu-
sion abnormalities is shown in Table 1.
Risk factors
Two women were moderately hypertensive, both with SPECT
changes. The cholesterol level was moderately higher in patients
with a positive SPECT examination compared to those, without
any abnormalities in coronary flow, but no relevant statistical di-
fference was found. The plasma levels of LDL and triglycerides
level was higher in subjects with abnormal myocardial perfusion.
The plasma homocysteine level was higher only in women with
positive antiphospholipid antibodies. The risk factors in women
with and without myocardial SPECT changes are shown in Tables
2 and 3.
Six women were cigarette smokers; 4 of them had perfusion
abnormalities in myocardial SPECT scanning. Nine women (age
36–49 years) were climacteric; 7 of them had changes in SPECT
scanning. Elevated titres of antiphospholipid antibodies and/or
lupus anti-coagulant (LAC) were found in 7 cases; in 6 of them
heart perfusion changes were observed. Those risk factors are
shown in Table 3.
Discussion
Our study showed abnormal myocardial flow in 12 individu-
als, more than half of the whole group. At rest, fixed myocardial
perfusion abnormalities were found in 7 individuals. In all these
cases no clinical symptoms and signs of coronary artery disease
were present. Similar studies were by Bruce et al [5, 6]. In this
group 38% of  the 129 asymptomatic patients had myocardial
perfusion SPECT abnormalities. 90% of patients had reversible
and 20% irreversible changes [6].
Assessing myocardial blood flow is useful in detecting heart
ischemia, depicting the extent of disease, prognosing and
Table 1. Localization of heart perfusion abnormalities SPECT in 12
women with systemic lupus erythomatosus and positive myocardial
perfusion SPECT scanning
Pt. no. Inferior wall Anterior wall Septum
1. + +
2. + +
3. +
4. + +
5. +
6. +
7. +
8. + +
9. +
10 +
11. +
12. + +
Table 2. Comparison of laboratory findings in patients with and
without myocardial perfusion SPECT changes
Group with Group without
SPECT changes SPECT changes
n = 12  n = 10
Cholesterol [mg/dl] 244.0 ± 56.09 207.0 ± 33.24
LDL [mg/dl] 155.0 ± 51.79 123.1 ± 25.44
HDL [mg/dl] 58.5 ± 11.8 63.0 ± 3.3
Triglycerides [mg/dl] 123.5 ± 47.4 93.5 ± 46.11
Homocysteine [µmol/l] 13.7 ± 4.4 13.5 ± 3.5
LDL — low density lipoprotein; HDL — high density lipoprotein
Table 3. Risk factors in women with SLE
Group with Group without
SPECT changes SPECT changes
n = 12 n = 10
Smoking (%) 4 (30%) 2 (20%)
Climacterium 7 (58%) 2 (20%)
Antyphospholipid antibodies 5 (42%) 1 (10%)
LAC 1 (8%) 0
LAC — lupus anticoagulant
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assessing the treatment efficiency in CAD. The assessment of myo-
cardial perfusion in women with SLE is far more complicated than
in other patients. Women more frequently complain of atypical
rest pain provoked by stress. Typical symptoms of coronary ar-
tery disease in common are: fatigue, general weakness, malaise
and chest pain [7]. In women with SLE non-ischemic chest pain is
also common, which makes the diagnostic even more complica-
ted. The causes of non-ischemic chest pain may be caused by
joint and/or muscular pain, pleural involvement and pain linked
with the thoracic vertebral column. Using commonly available
diagnostic tests, such as: electrocardiography and echocardio-
graphy, asymptomatic CAD can be detected in about 16% SLE
patients [5, 6]. The diagnostic value of resting electrocardiography
and echocardiography in detecting coronary artery disease
without heart infarction is limited even in patients with arterioscle-
rotic changes in coronary arteries [7]. In our study all patients with
changes of myocardial perfusion detected by SPECT had normal
resting electrocardiography. The value of exercise ECG testing
especially in young women is controversial as well. This is due to
the high prevalence of false positive results. In our study ECG
exercise test had no diagnostic value (apart from one case).  Per-
forming dobutamine echocardiography instead of ECG test may
help to exclude false positive results, especially in women [8].
Another problem of CAD in SLE is its pathology. Although in
autopsy, computed tomography and magnetic resonance ima-
ging arteriosclerotic plaques dominate as the most frequent fin-
ding, others mechanisms causing changes in coronary arteries
cannot be excluded [4, 9]. This could be vasculopathy due to
antiphospholipid syndrome and the formation of small blood clots
in arteries. This may stimulate arteriosclerotic changes and may
have an important impact on choosing the treatment methods.
In our study only women with asymptomatic coronary disease
were enrolled. The aim of early treatment of CAD is the modifica-
tion arteriosclerosis risk factors, which are different in different age
groups and between sexes. Risk factors like hypertension, diabe-
tes mellitus and obesity are far more common in women with SLE,
even in the pre-menopausal period; the use of corticosteroids and
limited physical activity are additional risk factors. There are many
indicative parameters linked with premature arteriosclerosis in
women with SLE such as increased levels of homocysteine, heat
shock proteins (HSP), b2 -glicoprotein I, antiphospholipid antibo-
dies and oxLDL antibodies [10, 11]. Lupus erythomatosus itself
as the inflammatory disease is regarded to be an independent
risk factor of arteriosclerosis.  In the active inflammatory phase of
the disease the arterial intima is affected and that is the triggering
point of the immunological reaction which initiates plaque forma-
tion arthrosclerosis.
In our study we found that a sub-group with changes in myo-
cardial perfusion had increased risk factors for CAD [7]. Most
CAD-asymptomatic women with myocardial perfusion SPECT
changes were climacteric, cigarette smokers and had positive
antiphospholipid antibodies or a high cholesterol level. These fin-
dings should be confirmed in larger population studies. In young
women with SLE different risk factors of arteriosclerosis should
be taken into consideration, before treatment is started. In pa-
tients with impaired myocardial flow arteriosclerosis prophylaxis
should be initiated as soon as possible.
Therefore, it seems that non-invasive diagnostic procedures
should be performed selectively in all SLE patients with risk fac-
tors. A separate issue, which is worth further study, is the role of
myocardial SPECT scanning in the risk stratification of patients
with SLE.
Conclusions
In young women with SLE and no symptoms of coronary ar-
tery disease myocardial pefusion defects may be detected by
means of myocardial perfusion scintigraphy. Exercise and resting
electrocardiography tests may not be sufficient for CAD diagno-
sis in women with SLE. The presence of coronary artery disease
risk factors in women with SLE could be an indication to perform
myocardial perfusion SPECT scanning.
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